Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404868 | 0.87 | NTRK1 (0.46) | HIF1AFLT3IRAK4MAPTLMNA | |
| SCHEMBL405515 | 0.85 | PIM1 (0.45) | FLT3IRAK4MAPTLMNANTRK1 | |
| SCHEMBL403247 | 0.85 | HIF1A (0.54) | HIF1AFLT3IRAK4MAPTLMNA | |
| SCHEMBL403713 | 0.84 | FYN (0.51) | FLT3IRAK4LMNANTRK1FYN | |
| SCHEMBL407024 | 0.83 | PIM1 (0.47) | HIF1AIRAK4NTRK1PIM1PIM3 | |
| SCHEMBL403904 | 0.83 | JAK2 (0.44) | FLT3IRAK4NTRK1PIM1PIM3 | |
| SCHEMBL401698 | 0.83 | HDAC3 (0.46) | FLT3IRAK4NTRK1PIM1PIM3 | |
| SCHEMBL406310 | 0.83 | NTRK1 (0.57) | FLT3IRAK4NTRK1JAK3 | |
| SCHEMBL400574 | 0.82 | NTRK1 (0.50) | FLT3IRAK4MAPTNTRK1FYN | |
| SCHEMBL402197 | 0.82 | NTRK1 (0.47) | IRAK4NTRK1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2962566-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2348860-B1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | HIF1A 2549/4885FLT3 16/4885IRAK4 9/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | HIF1A 2549/4885FLT3 16/4885IRAK4 9/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | HIF1A 2549/4885FLT3 16/4885IRAK4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.